A two-stage approach to the treatment of hyperuricemia in gout: The "dirty Dish" hypothesis

Arthritis and Rheumatism

Volumn 63, Issue 12, 2011, Pages 4002-4006

  Perez Ruiz, Fernando ^a   Herrero Beites, Ana Maria ^b   Carmona, Loreto ^c  

^a HOSPITAL DE CRUCES   (Spain)

^b Hospital de Gorliz   (Spain)

^c CAMILO JOSÉ CELA UNIVERSITY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; DIURETIC AGENT; FENOFIBRATE; LOSARTAN; NONSTEROID ANTIINFLAMMATORY AGENT; URIC ACID;

ADULT; ARTICLE; DRUG USE; FEMALE; FOLLOW UP; GOUT; HUMAN; HYPERURICEMIA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT FAILURE; URIC ACID BLOOD LEVEL; WEIGHT REDUCTION;

AGED; COHORT STUDIES; COLCHICINE; CRYSTALLIZATION; FEMALE; FENOFIBRATE; FOLLOW-UP STUDIES; GOUT; GOUT SUPPRESSANTS; HUMANS; HYPERURICEMIA; KAPLAN-MEIER ESTIMATE; LOSARTAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECURRENCE; REGRESSION ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; URIC ACID; WITHHOLDING TREATMENT;

EID: 82455210376     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.30649     Document Type: Article

References (13)

1. Perez-Ruiz F,. Treating to target: an strategy to cure gout. Rheumatology (Oxford) 2009; 48 Suppl 2: ii9-12.
2. Zhang W, Doherty M, Pascual E, Bardin T, Barskova V, Conagham P, et al. EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006; 65: 1312-24. (Pubitemid 44620440)
3. Pascual E, Sivera F,. Time required for disappearance of urate crystals from synovial fluid after successful hypouricaemic treatment relates to the duration of gout. Ann Rheum Dis 2007; 66: 1056-8. (Pubitemid 47122319)
4. Perez-Ruiz F, Atxotegi J, Hernando I, Calabozo M, Nolla JM,. Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. Arthritis Rheum 2006; 55: 786-90. (Pubitemid 44619193)
5. Shoji A, Yamanaka H, Kamatani N,. A retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy. Arthritis Rheum 2004; 51: 321-5. (Pubitemid 38725128)
6. Perez-Ruiz F, Liote F,. Lowering serum uric acid levels: what is the optimal target for improving clinical outcomes in gout? Arthritis Rheum 2007; 57: 1324-8. (Pubitemid 47585481)
7. Pascual E, Sivera F,. Why is gout so poorly managed? Ann Rheum Dis 2007; 66: 1269-70. (Pubitemid 47492466)
8. Luk AJ, Levin GP, Moore EE, Zhou XH, Kestenbaum BR, Choi HK,. Allopurinol and mortality in hyperuricaemic patients. Rheumatology (Oxford) 2009; 48: 804-6.
9. Beutler AM, Rull M, Schlesinger N, Baker DG, Hoffman BI, Schumacher HR Jr., Treatment with allopurinol decreases the number of acute gout attacks despite persistently elevated serum uric acid levels. Clin Exp Rheumatol 2001; 19: 595. (Pubitemid 32894613)
10. Sivera F, Aragon R, Pascual E,. First metatarsophalangeal joint aspiration using a 29-gauge needle. Ann Rheum Dis 2008; 46: 273-5. (Pubitemid 351183323)
11. Malik A, Schumacher HR, Dinnella JE, Clayburne GM,. Clinical diagnostic criteria for gout: comparison with the gold standard of synovial fluid crystal analysis. J Clin Rheumatol 2009; 15: 22-4.
12. Perez-Ruiz F,. New treatments for gout. Joint Bone Spine 2007; 74: 313-5. (Pubitemid 47053968)
13. Zhu Y, Zhang Y, Choi HK,. The serum urate-lowering impact of weight loss among men with a high cardiovascular risk profile: the Multiple Risk Factor Intervention Trial. Rheumatology (Oxford) 2010; 49: 2391-9.